Bio-Techne (TECH) Stock Buyback History
TTM buyback yield 1.23% · Shareholder yield (TTM) 1.23%.
TECH
TTM buyback yield
1.23%
Shareholder yield (TTM)
1.23%
5Y share count change
1.3%
TTM buyback spend
$100.08M
SBC coverage (TTM)
2.46x
YoY change in spend
+244.5%
5Y CAGR of spend
+40.6%
Peak year (2025)
$275.73M
Cumulative spend
$1.01B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- Bio-Techne (TECH) repurchased about $100.08M of stock over the trailing twelve months.
- Diluted share count is up 1.3% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 2.46× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +40.6% per year over the latest 5-year window.
- TTM repurchases used about 46% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $275.73M | $40.83M | $234.90M | 0.16B | -0.7% | 3.46% |
| 2024 | $80.04M | $38.04M | $42.00M | 0.16B | -0.7% | 0.71% |
| 2023 | $19.56M | $39.23M | −$19.67M | 0.16B | -1.4% | 0.15% |
| 2022 | $160.95M | $42.18M | $118.77M | 0.16B | 1.3% | 1.18% |
| 2021 | $43.18M | $48.98M | −$5.80M | 0.16B | 2.7% | 0.25% |
| 2020 | $50.11M | $32.37M | $17.75M | 0.16B | 1.3% | 0.50% |
| 2019 | $15.40M | $32.28M | −$16.88M | 0.16B | 2.2% | 0.19% |
| 2018 | $0.00 | $28.24M | −$28.24M | 0.15B | 1.5% | — |
| 2017 | $0.00 | $14.63M | −$14.63M | 0.15B | 0.5% | — |
| 2016 | $0.00 | $9.43M | −$9.43M | 0.15B | 0.3% | — |
| 2015 | $0.00 | $5.96M | −$5.96M | 0.15B | 0.6% | — |
| 2014 | $0.00 | $3.52M | −$3.52M | 0.15B | 0.3% | — |
| 2013 | $2.39M | $1.86M | $530.00K | 0.15B | -0.3% | 0.09% |
| 2012 | $24.50M | $1.64M | $22.86M | 0.15B | -0.4% | 0.90% |
| 2011 | $2.23M | $1.14M | $1.10M | 0.15B | -0.5% | 0.07% |
| 2010 | $15.58M | $1.14M | $14.45M | 0.15B | -1.5% | 0.73% |
| 2009 | $92.31M | $1.48M | $90.83M | 0.15B | -3.4% | 3.88% |
| 2008 | $60.19M | $0.00 | $60.19M | 0.16B | -0.7% | 2.01% |
| 2007 | $1.22M | $0.00 | $1.22M | 0.16B | -0.2% | 0.05% |
| 2006 | $27.27M | $0.00 | $27.27M | 0.16B | -3.2% | 1.36% |
| 2005 | $103.93M | $0.00 | $103.93M | 0.16B | -1.9% | 5.84% |
| 2004 | $0.00 | $0.00 | $0.00 | 0.17B | -0.8% | — |
| 2003 | $23.66M | $0.00 | $23.66M | 0.17B | -1.2% | 1.90% |
| 2002 | $745.62K | $0.00 | $745.62K | 0.17B | -0.3% | 0.06% |
| 2001 | $1.16M | $0.00 | $1.16M | 0.17B | 1.1% | 0.09% |
| 2000 | $0.00 | $0.00 | $0.00 | 0.17B | 2.0% | — |
| 1999 | $3.90M | $0.00 | $3.90M | 0.17B | 5.5% | — |
| 1998 | $300.00K | $0.00 | $300.00K | 0.16B | 0.7% | — |
| 1997 | $3.20M | $0.00 | $3.20M | 0.16B | 0.1% | — |
| 1996 | $700.00K | $0.00 | $700.00K | 0.16B | — | — |
| 1995 | $600.00K | $0.00 | $600.00K | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $200.00K | $0.00 | $200.00K | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1990 | $200.00K | $0.00 | $200.00K | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Bio-Techne (TECH) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Bio-Techne (TECH)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Bio-Techne (TECH)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $275.73M | +244.5% | +$195.69M | ||
| 2024 | $80.04M | +309.2% | +$60.48M | ||
| 2023 | $19.56M | -87.8% | -$141.39M | ||
| 2022 | $160.95M | +272.8% | +$117.77M | ||
| 2021 | $43.18M | -13.8% | -$6.93M | ||
| 2020 | $50.11M | +225.3% | +$34.71M | ||
| 2019 | $15.40M | — | +$15.40M | ||
| 2018 | $0 | — | $0 | ||
| 2017 | $0 | — | $0 | ||
| 2016 | $0 | — | $0 | ||
| 2015 | $0 | — | $0 | ||
| 2014 | $0 | -100.0% | -$2.39M | ||
| 2013 | $2.39M | -90.2% | -$22.11M | ||
| 2012 | $24.50M | +996.9% | +$22.27M | ||
| 2011 | $2.23M | -85.7% | -$13.35M | ||
| 2010 | $15.58M | -83.1% | -$76.73M | ||
| 2009 | $92.31M | +53.4% | +$32.12M | ||
| 2008 | $60.19M | +4825.7% | +$58.97M | ||
| 2007 | $1.22M | -95.5% | -$26.05M | ||
| 2006 | $27.27M | -73.8% | -$76.66M | ||
| 2005 | $103.93M | — | +$103.93M | ||
| 2004 | $0 | -100.0% | -$23.66M | ||
| 2003 | $23.66M | +3073.5% | +$22.92M | ||
| 2002 | $745,615 | -35.9% | -$418,153 | ||
| 2001 | $1.16M | — | +$1.16M | ||
| 2000 | $0 | -100.0% | -$3.90M | ||
| 1999 | $3.90M | +1200.0% | +$3.60M | ||
| 1998 | $300,000 | -90.6% | -$2.90M | ||
| 1997 | $3.20M | +357.1% | +$2.50M | ||
| 1996 | $700,000 | +16.7% | +$100,000 | ||
| 1995 | $600,000 | — | +$600,000 | ||
| 1994 | $0 | — | $0 | ||
| 1993 | $0 | -100.0% | -$200,000 | ||
| 1992 | $200,000 | — | +$200,000 | ||
| 1991 | $0 | -100.0% | -$200,000 | ||
| 1990 | $200,000 | — | — |
Bio-Techne (TECH) most recent annual buyback spend stands at $275.73M (2025) – surged 244.5% year-over-year.
Over 2020–2025 (5 years), Bio-Techne buyback spend expanded at a +40.6% compound annual rate, sustaining 2 straight years of year-over-year growth.
$275.73M stands as the all-time-high annual buyback spend, posted in 2025, against a low of $0 during 1991.
Bio-Techne (TECH) sits 8th of 8 Healthcare peers we track on this metric, against a peer median of $2.75B.
Bio-Techne Buyback Spend 2025: $275.73M
Bio-Techne buyback spend in 2025 was $275.73M, surged 244.5% from 2024. This figure represents the highest annual value in the available history.
Bio-Techne Buyback Spend 2024: $80.04M
Bio-Techne buyback spend in 2024 was $80.04M, surged 309.2% from 2023.
Bio-Techne Buyback Spend 2023: $19.56M
Bio-Techne buyback spend in 2023 was $19.56M, plunged 87.8% below 2022.
Bio-Techne Buyback Spend 2022: $160.95M
Bio-Techne buyback spend in 2022 was $160.95M, surged 272.8% from 2021.
Bio-Techne Buyback Spend 2021: $43.18M
Bio-Techne buyback spend in 2021 was $43.18M.
See more financial history for Bio-Techne (TECH).
Sector peers by buyback spend
Companies in the same sector as Bio-Techne, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 2.46×.
Capital allocation mix
How Bio-Techne splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $219.78M (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Bio-Techne's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Bio-Techne buy back its own stock?
Yes, Bio-Techne (TECH) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does Bio-Techne spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $100.08M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is Bio-Techne's buyback yield?
TTM buyback yield is about 1.23% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is Bio-Techne's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 1.23% combined (TTM-based where available).
Is Bio-Techne diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Bio-Techne's share count changed?
Diluted weighted average shares changed by about 1.3% over roughly five fiscal years (annual income statement data).
What is Bio-Techne's buyback spend?
Latest reported buyback spend for Bio-Techne (TECH) is $100.08M (period ending March 31, 2026).
How has Bio-Techne buyback spend changed year-over-year?
Bio-Techne (TECH) buyback spend changed +244.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Bio-Techne buyback spend?
Bio-Techne (TECH) buyback spend compound annual growth rate is +40.6% over the most recent 5 years available.
When did Bio-Techne buyback spend hit its highest annual value?
Bio-Techne buyback spend reached its highest annual value of $275.73M in 2025.
What was Bio-Techne buyback spend in 2024?
Bio-Techne (TECH) buyback spend in 2024 was $80.04M.
What was Bio-Techne buyback spend in 2025?
Bio-Techne (TECH) buyback spend in 2025 was $275.73M.
Explore more
TECH Overview
Company profile, financial tools, and key metrics
TECH Revenue Counter
Earns $38.39 every second. See per minute, hour, and day.
TECH Earnings Counter
Earns $3.47 per second net profit. See per minute, hour, and day.
TECH Economic Scale
Exceeds Samoa's GDP. Compare with world economies.
TECH What If Invested
What if you had invested $1,000? See historical returns from any date.
TECH How It Makes Money
Discover visual breakdown of $1.21B in revenue — where it comes from and where it goes.
TECH Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
TECH Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
TECH Daily Price Character
Balanced · 45.3% historical win rate (green days). Streaks & record days.
TECH Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.
TECH Dividend Profile
Yield: 0.69%. Safety: 5/8. See full history.
TECH Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
TECH Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.
TECH Dividend Capture
Historical pre-ex touch stats, gap distribution, after-tax calculator, and a backtest simulator (limit-order vs MOC exit).
TECH Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.